Literature DB >> 28333238

Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys.

D H Abbott1,2, B H Rayome2, D A Dumesic3, K C Lewis4, A K Edwards2, K Wallen5,6, M E Wilson5, S E Appt7, J E Levine2,8.   

Abstract

Study question: Do naturally occurring, hyperandrogenic (≥1 SD of population mean testosterone, T) female rhesus monkeys exhibit traits typical of women with polycystic ovary syndrome (PCOS)? Summary answer: Hyperandrogenic female monkeys exhibited significantly increased serum levels of androstenedione (A4), 17-hydroxyprogesterone (17-OHP), estradiol (E2), LH, antimullerian hormone (AMH), cortisol, 11-deoxycortisol and corticosterone, as well as increased uterine endometrial thickness and evidence of reduced fertility, all traits associated with PCOS. What is known already: Progress in treating women with PCOS is limited by incomplete knowledge of its pathogenesis and the absence of naturally occurring PCOS in animal models. A female macaque monkey, however, with naturally occurring hyperandrogenism, anovulation and polyfollicular ovaries, accompanied by insulin resistance, increased adiposity and endometrial hyperplasia, suggests naturally occurring origins for PCOS in nonhuman primates. Study design, size, duration: As part of a larger study, circulating serum concentrations of selected pituitary, ovarian and adrenal hormones, together with fasted insulin and glucose levels, were determined in a single, morning blood sample obtained from 120 apparently healthy, ovary-intact, adult female rhesus monkeys (Macaca mulatta) while not pregnant or nursing. The monkeys were then sedated for somatometric and ultrasonographic measurements. Participants/materials, setting, methods: Female monkeys were of prime reproductive age (7.2 ± 0.1 years, mean ± SEM) and represented a typical spectrum of adult body weight (7.4 ± 0.2 kg; maximum 12.5, minimum 4.6 kg). Females were defined as having normal (n = 99) or high T levels (n = 21; ≥1 SD above the overall mean, 0.31 ng/ml). Electronic health records provided menstrual and fecundity histories. Steroid hormones were determined by tandem LC-MS-MS; AMH was measured by enzymeimmunoassay; LH, FSH and insulin were determined by radioimmunoassay; and glucose was read by glucose meter. Most analyses were limited to 80 females (60 normal T, 20 high T) in the follicular phase of a menstrual cycle or anovulatory period (serum progesterone <1 ng/ml). Main results and the role of chance: Of 80 monkeys, 15% (n = 12) exhibited classifiable PCOS-like phenotypes. High T females demonstrated elevations in serum levels of LH (P < 0.036), AMH (P < 0.021), A4 (P < 0.0001), 17-OHP (P < 0.008), E2 (P < 0.023), glucocorticoids (P < 0.02-0.0001), the serum T/E2 ratio (P < 0.03) and uterine endometrial thickness (P < 0.014) compared to normal T females. Within the high T group alone, anogenital distance, a biomarker for fetal T exposure, positively correlated (P < 0.015) with serum A4 levels, while clitoral volume, a biomarker for prior T exposure, positively correlated (P < 0.002) with postnatal age. Only high T females demonstrated positive correlations between serum LH, and both T and A4. Five of six (83%) high T females with serum T ≥2 SD above T mean (0.41 ng/ml) did not produce live offspring. Large scale data: N/A. Limitations, reasons for caution: This is an initial study of a single laboratory population in a single nonhuman primate species. While two biomarkers suggest lifelong hyperandrogenism, phenotypic expression during gestation, prepuberty, adolescence, mid-to-late reproductive years and postmenopause has yet to be determined. Wider implications of the findings: Characterizing adult female monkeys with naturally occurring hyperandrogenism has identified individuals with high LH and AMH combined with infertility, suggesting developmental linkage among traits with endemic origins beyond humans. PCOS may thus be an ancient phenotype, as previously proposed, with a definable pathogenic mechanism(s). Study funding/competing interest(s): Funded by competitive supplement to P51 OD011106 (PI: Mallick), by P50 HD028934 (PI: Marshall) and by P50 HD044405 (PI: Dunaif). The authors have no potential conflicts of interest.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  developmental programming; enlarged uterine endothelium; high AMH; hypergonadotropic; hypersteroidogenic; infertility

Mesh:

Substances:

Year:  2017        PMID: 28333238      PMCID: PMC6251677          DOI: 10.1093/humrep/dex036

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  120 in total

1.  Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent.

Authors:  D R Session; K R Kalli; I S Tummon; M A Damario; D A Dumesic
Journal:  Gynecol Endocrinol       Date:  2003-10       Impact factor: 2.260

Review 2.  Steroidogenic versus Metabolic Programming of Reproductive Neuroendocrine, Ovarian and Metabolic Dysfunctions.

Authors:  Rodolfo C Cardoso; Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Neuroendocrinology       Date:  2015-04-01       Impact factor: 4.914

3.  Fetal programming of body composition: relation between birth weight and body composition measured with dual-energy X-ray absorptiometry and anthropometric methods in older Englishmen.

Authors:  Osama A Kensara; Steve A Wootton; David I Phillips; Mayke Patel; Alan A Jackson; Marinos Elia
Journal:  Am J Clin Nutr       Date:  2005-11       Impact factor: 7.045

Review 4.  Evolutionary determinants of polycystic ovary syndrome: part 2.

Authors:  Daniel M T Fessler; Barbara Natterson-Horowitz; Ricardo Azziz
Journal:  Fertil Steril       Date:  2016-05-28       Impact factor: 7.329

Review 5.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

6.  Reproductive adaptations to a large-brained fetus open a vulnerability to anovulation similar to polycystic ovary syndrome.

Authors:  Deborah K Barnett; David H Abbott
Journal:  Am J Hum Biol       Date:  2003 May-Jun       Impact factor: 1.937

Review 7.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

Review 8.  Adrenal Hyperandrogenism and Polycystic Ovary Syndrome.

Authors:  Manuel Luque-Ramírez; Héctor F Escobar-Morreale
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

9.  Abnormal infant islet morphology precedes insulin resistance in PCOS-like monkeys.

Authors:  Lindsey E Nicol; Timothy D O'Brien; Daniel A Dumesic; Tristan Grogan; Alice F Tarantal; David H Abbott
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

10.  Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations.

Authors:  M Geoffrey Hayes; Margrit Urbanek; David A Ehrmann; Loren L Armstrong; Ji Young Lee; Ryan Sisk; Tugce Karaderi; Thomas M Barber; Mark I McCarthy; Stephen Franks; Cecilia M Lindgren; Corrine K Welt; Evanthia Diamanti-Kandarakis; Dimitrios Panidis; Mark O Goodarzi; Ricardo Azziz; Yi Zhang; Roland G James; Michael Olivier; Ahmed H Kissebah; Elisabet Stener-Victorin; Richard S Legro; Andrea Dunaif
Journal:  Nat Commun       Date:  2015-08-18       Impact factor: 14.919

View more
  20 in total

1.  Female Offspring From Chronic Hyperandrogenemic Dams Exhibit Delayed Puberty and Impaired Ovarian Reserve.

Authors:  Zhiqiang Wang; Mingjie Shen; Ping Xue; Sara A DiVall; James Segars; Sheng Wu
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

2.  Neuronal androgen receptor: Molecular gateway to polycystic ovary syndrome?

Authors:  David H Abbott
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-04       Impact factor: 11.205

Review 3.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

Review 4.  Emerging Roles of Anti-Müllerian Hormone in Hypothalamic-Pituitary Function.

Authors:  Anne-Laure Barbotin; Maëliss Peigné; Samuel Andrew Malone; Paolo Giacobini
Journal:  Neuroendocrinology       Date:  2019-07-05       Impact factor: 4.914

Review 5.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

6.  Metformin use in polycystic ovary syndrome pregnancy impacts on offspring obesity.

Authors:  David H Abbott
Journal:  Lancet Child Adolesc Health       Date:  2019-01-29

Review 7.  In utero Androgen Excess: A Developmental Commonality Preceding Polycystic Ovary Syndrome?

Authors:  David H Abbott; Marissa Kraynak; Daniel A Dumesic; Jon E Levine
Journal:  Front Horm Res       Date:  2019-09-09       Impact factor: 2.606

8.  Maternal urinary levels of glyphosate during pregnancy and anogenital distance in newborns in a US multicenter pregnancy cohort.

Authors:  Corina Lesseur; Patrick Pirrotte; Khyatiben V Pathak; Fabiana Manservisi; Daniele Mandrioli; Fiorella Belpoggi; Simona Panzacchi; Qian Li; Emily S Barrett; Ruby H N Nguyen; Sheela Sathyanarayana; Shanna H Swan; Jia Chen
Journal:  Environ Pollut       Date:  2021-03-22       Impact factor: 9.988

Review 9.  The role of gonadotropin-releasing hormone neurons in polycystic ovary syndrome.

Authors:  Christopher R McCartney; Rebecca E Campbell; John C Marshall; Suzanne M Moenter
Journal:  J Neuroendocrinol       Date:  2022-01-26       Impact factor: 3.870

10.  Abnormal GnRH Pulsatility in Polycystic Ovary Syndrome: Recent Insights.

Authors:  Christopher R McCartney; Rebecca E Campbell
Journal:  Curr Opin Endocr Metab Res       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.